<!doctype html><html lang=zh-tw><head><meta charset=utf-8><meta name=description content="[!info]
ğŸŒ± ä¾†è‡ª: [[colorectal cancer]]
 Metastatic Colon Cancer  [[ESMO guidelines of Metastatic Colon Cancer]] ó°’—
  Chemotherapy for advanced and metastatic disease Definitions:  [[FOLFOX]]:  Infusional [[Fluorouracil]] 5-FU/LV [[FULV]] +  AEs_5FU: ğŸ’©ğŸ‘„ğŸ¤®ğŸ©¸ğŸ¤ğŸ«€ğŸ‘ï¸ğŸ–ï¸ğŸ¦¶ğŸ˜‡ğŸŒ   [[Oxaliplatin]]   [[FOLFIRI]]: Infusional 5-FU/LV + [[Irinotecan]]; [[FOLFOXIRI]]: Infusional 5-FU/LV + OX + irinotecan; CAPEOX: [[Capecitabine]] Diarrhea, HFS, (5FU pro, 3 steps to convert to 5FU, same aE) + OX  Xeloda 500mg/tab 1200mg/BSA     1st line: [[FOLFOX]] (JCO 2004;22:23) Â± [[Bevacizumab]] (JCO 2008;26:2013); [[CAPEOX]]; FOLFIRI (JCO 2004;22:229) Â± Bev (JCO 2007;25:4779); FOLFOXIRI Â± Bev ([[TRIBE]], NEJM 2014;371:1609) [[anti-VEGF]]: è¡€æ “å‡ºè¡€è›‹ç™½å°¿ã€è¡“å¾Œå‚·å£é«˜è¡€å£“ For pts w/ L-sided CRC & wt [[RAS]]/[[BRAF]]: FOLFOX or FOLFIRI Â± [[cetuximab]]/[[panitumumab]] ([[CRYSTAL]], NEJM 2009;360:1408; [[PRIME]], JCO 2010;28:4697)  R-sided CRC: C,A,T [[cetuximab vs bevacizumab]]:  [[FIRE-3]] 28."><meta property="og:title" content><meta property="og:description" content><meta property="og:type" content="website"><meta property="og:url" content><meta property="og:image" content="https://og-mlkgi530p-htlin222.vercel.app/api/blog?templateTitle=Metastatic Colon Cancer"><title>Metastatic Colon Cancer</title><meta name=viewport content="width=device-width,initial-scale=1"><link rel=alternate type=application/rss+xml href=https://www.physician.tw//feed.xml title><link rel="shortcut icon" type=image/png href=https://www.physician.tw//icon.png><link href=https://www.physician.tw/styles.acd6336f837a791cf1889bb120dfb142.min.css rel=stylesheet><link href=https://www.physician.tw/styles/_light_syntax.86a48a52faebeaaf42158b72922b1c90.min.css rel=stylesheet id=theme-link><script src=https://www.physician.tw/js/darkmode.dfadb738e747a87e78c7144d7267f1bc.min.js></script>
<script src=https://www.physician.tw/js/util.6f22941e242efae60fd84e7c32e874fa.min.js></script>
<link rel=preload href=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.css as=style onload='this.onload=null,this.rel="stylesheet"' integrity=sha384-R4558gYOUz8mP9YWpZJjofhk+zx0AS11p36HnD2ZKj/6JR5z27gSSULCNHIRReVs crossorigin=anonymous><script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.js integrity=sha384-z1fJDqw8ZApjGO3/unPWUPsIymfsJmyrDVWC8Tv/a1HeOtGmkwNd/7xUS0Xcnvsx crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/contrib/auto-render.min.js integrity=sha384-+XBljXPPiv+OzfbB3cVmLHf4hdUFHlWNZN5spNQ7rmHTXpd7WvJum6fIACpNNfIR crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.16.2/dist/contrib/copy-tex.min.js integrity=sha384-ww/583aHhxWkz5DEVn6OKtNiIaLi2iBRNZXfJRiY1Ai7tnJ9UXpEsyvOITVpTl4A crossorigin=anonymous></script>
<script async src=https://unpkg.com/@floating-ui/core@0.7.3></script>
<script async src=https://unpkg.com/@floating-ui/dom@0.5.4></script>
<script async src=https://www.physician.tw/js/popover.f03552ccb84d99ca615d1cfb9abde59e.min.js></script>
<script defer src=https://www.physician.tw/js/code-title.ce4a43f09239a9efb48fee342e8ef2df.min.js></script>
<script defer src=https://www.physician.tw/js/clipboard.2913da76d3cb21c5deaa4bae7da38c9f.min.js></script>
<script defer src=https://www.physician.tw/js/callouts.7723cac461d613d118ee8bb8216b9838.min.js></script>
<script>const SEARCH_ENABLED=!1,LATEX_ENABLED=!0,PRODUCTION=!0,BASE_URL="https://www.physician.tw/",fetchData=Promise.all([fetch("https://www.physician.tw/indices/linkIndex.aa8c081727de296f4eab0c29bb65f75f.min.json").then(e=>e.json()).then(e=>({index:e.index,links:e.links})),fetch("https://www.physician.tw/indices/contentIndex.037c48be6936837c6b90839cb781d6b7.min.json").then(e=>e.json())]).then(([{index:e,links:t},n])=>({index:e,links:t,content:n})),render=()=>{const e=new URL(BASE_URL),t=e.pathname,n=window.location.pathname,s=t==n;addCopyButtons(),addTitleToCodeBlocks(),addCollapsibleCallouts(),initPopover("https://www.physician.tw",!0);const o=document.getElementById("footer");if(o){const e=document.getElementById("graph-container");if(!e)return requestAnimationFrame(render);e.textContent="";const t=s&&!1;drawGraph("https://www.physician.tw",t,[{"/moc":"#4388cc"}],t?{centerForce:1,depth:-1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.5,linkDistance:1,opacityScale:3,repelForce:1,scale:1.4}:{centerForce:1,depth:1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.6,linkDistance:1,opacityScale:3,repelForce:2,scale:1.2})}},init=(e=document)=>{addCopyButtons(),addTitleToCodeBlocks(),renderMathInElement(e.body,{delimiters:[{left:"$$",right:"$$",display:!0},{left:"$",right:"$",display:!1}],macros:{'â€™':"'"},throwOnError:!1})}</script><script type=module>
    import { attachSPARouting } from "https:\/\/www.physician.tw\/js\/router.9d4974281069e9ebb189f642ae1e3ca2.min.js"
    attachSPARouting(init, render)
  </script></head><body><div id=search-container><div id=search-space><input autocomplete=off id=search-bar name=search type=text aria-label=æœå°‹ placeholder="è«‹è¼¸å…¥åƒæ˜¯ï¼šhypertension ä¹‹é¡çš„ä¾†çœ‹æ²’æœ‰æ²’ä»€éº¼æœ‰è¶£çš„ğŸ³"><div id=results-container></div></div></div><script src=https://cdn.jsdelivr.net/npm/flexsearch@0.7.21/dist/flexsearch.bundle.js integrity="sha256-i3A0NZGkhsKjVMzFxv3ksk0DZh3aXqu0l49Bbh0MdjE=" crossorigin=anonymous defer></script>
<script defer src=https://www.physician.tw/js/full-text-search.e6e2e0c213187ca0c703d6e2c7a77fcd.min.js></script><div class=singlePage><header><h1 id=page-title><a href=https://www.physician.tw/>èœ¥èœ´èŠ±åœ’ğŸ¦ğŸŒ±ğŸª´ğŸŒ²</a></h1><div class=spacer></div><div id=search-icon><p>æœå°‹</p><svg tabindex="0" aria-labelledby="title desc" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 19.9 19.7"><title id="title">æœå°‹åœ–ç¤º</title><desc id="desc">æ‰“é–‹æœå°‹åœ–æ¨™</desc><g class="search-path" fill="none"><path stroke-linecap="square" d="M18.5 18.3l-5.4-5.4"/><circle cx="8" cy="8" r="7"/></g></svg></div><div class=darkmode><input class=toggle id=darkmode-toggle type=checkbox tabindex=-1>
<label id=toggle-label-light for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="dayIcon" viewBox="0 0 35 35" style="enable-background:new 0 0 35 35"><title>æ˜äº®æ¨¡å¼</title><path d="M6 17.5C6 16.672 5.328 16 4.5 16h-3C.672 16 0 16.672.0 17.5S.672 19 1.5 19h3C5.328 19 6 18.328 6 17.5zM7.5 26c-.414.0-.789.168-1.061.439l-2 2C4.168 28.711 4 29.086 4 29.5 4 30.328 4.671 31 5.5 31c.414.0.789-.168 1.06-.44l2-2C8.832 28.289 9 27.914 9 27.5 9 26.672 8.329 26 7.5 26zm10-20C18.329 6 19 5.328 19 4.5v-3C19 .672 18.329.0 17.5.0S16 .672 16 1.5v3C16 5.328 16.671 6 17.5 6zm10 3c.414.0.789-.168 1.06-.439l2-2C30.832 6.289 31 5.914 31 5.5 31 4.672 30.329 4 29.5 4c-.414.0-.789.168-1.061.44l-2 2C26.168 6.711 26 7.086 26 7.5 26 8.328 26.671 9 27.5 9zM6.439 8.561C6.711 8.832 7.086 9 7.5 9 8.328 9 9 8.328 9 7.5c0-.414-.168-.789-.439-1.061l-2-2C6.289 4.168 5.914 4 5.5 4 4.672 4 4 4.672 4 5.5c0 .414.168.789.439 1.06l2 2.001zM33.5 16h-3c-.828.0-1.5.672-1.5 1.5s.672 1.5 1.5 1.5h3c.828.0 1.5-.672 1.5-1.5S34.328 16 33.5 16zM28.561 26.439C28.289 26.168 27.914 26 27.5 26c-.828.0-1.5.672-1.5 1.5.0.414.168.789.439 1.06l2 2C28.711 30.832 29.086 31 29.5 31c.828.0 1.5-.672 1.5-1.5.0-.414-.168-.789-.439-1.061l-2-2zM17.5 29c-.829.0-1.5.672-1.5 1.5v3c0 .828.671 1.5 1.5 1.5s1.5-.672 1.5-1.5v-3C19 29.672 18.329 29 17.5 29zm0-22C11.71 7 7 11.71 7 17.5S11.71 28 17.5 28 28 23.29 28 17.5 23.29 7 17.5 7zm0 18c-4.136.0-7.5-3.364-7.5-7.5s3.364-7.5 7.5-7.5 7.5 3.364 7.5 7.5S21.636 25 17.5 25z"/></svg></label><label id=toggle-label-dark for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="nightIcon" viewBox="0 0 100 100" style="enable-background='new 0 0 100 100'"><title>é»‘æš—æ¨¡å¼</title><path d="M96.76 66.458c-.853-.852-2.15-1.064-3.23-.534-6.063 2.991-12.858 4.571-19.655 4.571C62.022 70.495 50.88 65.88 42.5 57.5 29.043 44.043 25.658 23.536 34.076 6.47c.532-1.08.318-2.379-.534-3.23-.851-.852-2.15-1.064-3.23-.534-4.918 2.427-9.375 5.619-13.246 9.491-9.447 9.447-14.65 22.008-14.65 35.369.0 13.36 5.203 25.921 14.65 35.368s22.008 14.65 35.368 14.65c13.361.0 25.921-5.203 35.369-14.65 3.872-3.871 7.064-8.328 9.491-13.246C97.826 68.608 97.611 67.309 96.76 66.458z"/></svg></label></div></header><article><h1>Metastatic Colon Cancer</h1><p class=meta>æœ€å¾Œæ›´æ–°æ–¼
Aug 23, 2023
<a href=https://github.com/htlin222/garden/tree/hugo/content/Metastatic%20Colon%20Cancer.md rel=noopener>ğŸªš ç·¨è¼¯åŸå§‹æ–‡ä»¶</a></p><ul class=tags><li><a href=https://www.physician.tw/tags/building/>building</a></li></ul><blockquote class=info-callout><p></p><p>ğŸŒ± ä¾†è‡ª: <a href=/colorectal-cancer rel=noopener class=internal-link data-src=/colorectal-cancer>colorectal cancer</a></p></blockquote><a href=#metastatic-colon-cancer><h1 id=metastatic-colon-cancer><span class=hanchor arialabel=Anchor># </span>Metastatic Colon Cancer</h1></a><blockquote><p><a href=/esmo-guidelines-of-metastatic-colon-cancer rel=noopener class=internal-link data-src=/esmo-guidelines-of-metastatic-colon-cancer>ESMO guidelines of Metastatic Colon Cancer</a> ó°’—</p></blockquote><ul><li>Chemotherapy for advanced and metastatic disease</li><li>Definitions:<ul><li><a href=/folfox rel=noopener class=internal-link data-src=/folfox>FOLFOX</a>:<ul><li>Infusional <a href=/fluorouracil rel=noopener class=internal-link data-src=/fluorouracil>Fluorouracil</a> 5-FU/LV <a href=/full rel=noopener class=internal-link data-src=/full>FULV</a> +<ul><li>AEs_5FU: ğŸ’©ğŸ‘„ğŸ¤®ğŸ©¸ğŸ¤ğŸ«€ğŸ‘ï¸ğŸ–ï¸ğŸ¦¶ğŸ˜‡ğŸŒ</li></ul></li><li><a href=/oxaliplatin rel=noopener class=internal-link data-src=/oxaliplatin>Oxaliplatin</a></li></ul></li><li><a href=/folfiri rel=noopener class=internal-link data-src=/folfiri>FOLFIRI</a>: Infusional 5-FU/LV + <a href=/irinotecan rel=noopener class=internal-link data-src=/irinotecan>Irinotecan</a>;</li><li><a href=/folfoxiri rel=noopener class=internal-link data-src=/folfoxiri>FOLFOXIRI</a>: Infusional 5-FU/LV + OX + irinotecan;</li><li>CAPEOX: <a href=/capecitabine rel=noopener class=internal-link data-src=/capecitabine>Capecitabine</a> Diarrhea, HFS, (5FU pro, 3 steps to convert to 5FU, same aE) + OX<ul><li>Xeloda 500mg/tab 1200mg/BSA</li></ul></li></ul></li><li>1st line: <a href=/folfox rel=noopener class=internal-link data-src=/folfox>FOLFOX</a> (JCO 2004;22:23) Â± <a href=/bevacizumab rel=noopener class=internal-link data-src=/bevacizumab>Bevacizumab</a> (JCO 2008;26:2013); <a href=/capeox rel=noopener class=internal-link data-src=/capeox>CAPEOX</a>; FOLFIRI (JCO 2004;22:229) Â± Bev (JCO 2007;25:4779); FOLFOXIRI Â± Bev (<a href=/tribe rel=noopener class=internal-link data-src=/tribe>TRIBE</a>, NEJM 2014;371:1609)</li><li><a href=/anti-vegf rel=noopener class=internal-link data-src=/anti-vegf>anti-VEGF</a>: è¡€æ “å‡ºè¡€è›‹ç™½å°¿ã€è¡“å¾Œå‚·å£é«˜è¡€å£“</li><li>For pts w/ L-sided CRC & wt <a href=/ras rel=noopener class=internal-link data-src=/ras>RAS</a>/<a href=/braf rel=noopener class=internal-link data-src=/braf>BRAF</a>: FOLFOX or FOLFIRI Â± <a href=/cetuximab rel=noopener class=internal-link data-src=/cetuximab>cetuximab</a>/<a href=/panitumumab rel=noopener class=internal-link data-src=/panitumumab>panitumumab</a> (<a href=/crystal rel=noopener class=internal-link data-src=/crystal>CRYSTAL</a>, NEJM 2009;360:1408; <a href=/prime rel=noopener class=internal-link data-src=/prime>PRIME</a>, JCO 2010;28:4697)<ul><li>R-sided CRC: C,A,T</li><li><a href=/cetuximab-vs-bevacizumab rel=noopener class=internal-link data-src=/cetuximab-vs-bevacizumab>cetuximab vs bevacizumab</a>:<ul><li><a href=/fire rel=noopener class=internal-link data-src=/fire>FIRE-3</a> 28.7 month</li><li><a href=/calgb-swog rel=noopener class=internal-link data-src=/calgb-swog>CALGB-SWOG 80405</a> 30 month</li><li><a href=/paradigm rel=noopener class=internal-link data-src=/paradigm>PARADIGM</a> 37.9 vs 34.3</li></ul></li></ul></li><li>If pts not appropriate for intense Rx: Infusional 5-FU/LV; Cape</li><li>2nd line:<ul><li>FOLFIRI or irinotecan for pts who received prior FOLFOX;</li><li>FOLFOX/CAPEOX for pts w/ prior FOLFIRI;<ul><li><a href=/gercor rel=noopener class=internal-link data-src=/gercor>GERCOR</a></li></ul></li><li>FOLFOX/CAPEOX, or FOLFIRI for prior 5-FU/LV or Cape;</li><li>all regimens Â±<ul><li>Bev/ziv-<a href=/aflibercept rel=noopener class=internal-link data-src=/aflibercept>aflibercept</a>/<a href=/ramucirumab rel=noopener class=internal-link data-src=/ramucirumab>ramucirumab</a><ul><li>Bev 11.2 vs 9.8: <a href=/ml rel=noopener class=internal-link data-src=/ml>ML18147</a></li><li>ziv-aflib 4mg/kg 13.5 vs 12.6: <a href=/velour rel=noopener class=internal-link data-src=/velour>VELOUR</a> agranulocytosis</li><li>ramu 13.6 vs 11.7: <a href=/raise rel=noopener class=internal-link data-src=/raise>RAISE</a></li></ul></li><li>(note that Bev is â†’ preferred over ziv-<a href=/aflibercept rel=noopener class=internal-link data-src=/aflibercept>aflibercept</a>/<a href=/ramucirumab rel=noopener class=internal-link data-src=/ramucirumab>ramucirumab</a> because of tox &/or cost);</li></ul></li><li>irinotecan-based regimens Â±;</li><li>cetuximab/panitumumab if not previously used<ul><li>phase III, continued use of bevacizumab plus standard second-line chemotherapy in patients with metastatic colorectal cancer progressing after standard first-line bevacizumab-based treatment.</li></ul></li><li><a href=/brite rel=noopener class=internal-link data-src=/brite>BRiTE</a> BRiTE observational cohort study</li></ul></li></ul><hr><ul><li>3rd line: Irinotecan Â± panitumumab/cetuximab (<a href=/bond rel=noopener class=internal-link data-src=/bond>BOND</a>, NEJM 2004;351:337) or single-agent panitumumab/cetuximab, or single-agent <a href=/regorafenib rel=noopener class=internal-link data-src=/regorafenib>regorafenib</a> or <a href=/tas rel=noopener class=internal-link data-src=/tas>TAS-102</a>; overall benefits of regorafenib or TAS-102 are modest w/ significant s/e<ul><li><a href=/correct rel=noopener class=internal-link data-src=/correct>CORRECT</a> 160mg/day for three week in 28d cycle â™»ï¸</li><li><a href=/recourse rel=noopener class=internal-link data-src=/recourse>RECOURSE</a> 35/BSA 1-5 8-15 in 28d cycle â™»ï¸</li></ul></li><li>1st line for MSI-H/dMMR: Pembrolizumab ([[KEY line for MSI-JM 2020;383:2207) or nivolumab Â± ipilimumab (<a href=/checkmate rel=noopener class=internal-link data-src=/checkmate>CHECKMATE 142</a>, Lancet Oncol 2017;18:1182)</li><li>Later line for <a href=/nice-ve rel=noopener class=internal-link data-src=/nice-ve>BRAF V600E</a> mut: <a href=/encorafenib rel=noopener class=internal-link data-src=/encorafenib>encorafenib</a> + cetuximab/panitumumab (<a href=/beacon rel=noopener class=internal-link data-src=/beacon>BEACON</a>, NEJM 2019;381:1632); addition of binimetinib did not improve OS or ORR</li><li>Later line for HER2 amplified & RAS/BRAF wildtype: Trastuzumab + pertuzumab; trastuzumab + lapatinib; trastuzumab deruxtecan</li><li>For FOLFOX, OX should be discontinued after first 3 mos of Rx till progression to reduce risk of severe neurotoxicity. Can be resumed at â†£ or after progression (OPTIMOX1, JCO 2006;24:394)</li><li>Do not use concurrent anti-EGFR + anti-VEGF Rx (CAIRO2, NEJM 2009;360:563)</li><li>Do not use anti-EGFR Rx in RAS/BRAF mut or any R sided CRC (JCO 2016;34(suppl, abstr 3504, 3505, 3506; JAMA Oncol 2017;3:211)</li><li>For pts progressing on anti-EGFR, use of anti-EGFR is â†’ not rec in subsequent lines</li></ul><a href=#uptodate-links-of-metastatic-colon-canceruptodate-links-><h2 id=uptodate-links-of-metastatic-colon-canceruptodate-links-><span class=hanchor arialabel=Anchor># </span><a href=/uptodate-links-of-metastatic-colon-cancer rel=noopener class=internal-link data-src=/uptodate-links-of-metastatic-colon-cancer>UpToDate Links</a> ó°’–</h2></a></article><hr><div class=page-end id=footer><div class=backlinks-container><h3>â†©ï¸ åå‘é€£çµ</h3><ul class=backlinks><li>ğŸ¤­æ²’æœ‰æ‰¾åˆ°åå‘é€£çµ</li></ul></div><div><script async src=https://cdn.jsdelivr.net/npm/d3@6.7.0/dist/d3.min.js integrity="sha256-+7jaYCp29O1JusNWHaYtgUn6EhuP0VaFuswhNV06MyI=" crossorigin=anonymous></script><h3>ğŸ¤¯äº’å‹•åœ–</h3><div id=graph-container></div><style>:root{--g-node:var(--secondary);--g-node-active:var(--primary);--g-node-inactive:var(--visited);--g-link:var(--outlinegray);--g-link-active:#5a7282}</style><script src=https://www.physician.tw/js/graph.2d9e48dbe7ea47c0ef1c58296ce14448.js></script></div></div><div><div id=disqus_thread></div><script type=application/javascript>window.disqus_config=function(){},function(){if(["localhost","127.0.0.1"].indexOf(window.location.hostname)!=-1){document.getElementById("disqus_thread").innerHTML="Disqus comments not available by default when the website is previewed locally.";return}var t=document,e=t.createElement("script");e.async=!0,e.src="//physician.disqus.com/embed.js",e.setAttribute("data-timestamp",+new Date),(t.head||t.body).appendChild(e)}()</script><noscript>Please enable JavaScript to view the <a href=https://disqus.com/?ref_noscript>comments powered by Disqus.</a></noscript><a href=https://disqus.com class=dsq-brlink>comments powered by <span class=logo-disqus>Disqus</span></a></div><div id=contact_buttons><footer><p>æœ¬ç¶²ç«™æ˜¯ç”± Hsieh-Ting Lin ä»¥â¤ï¸ ç”¨ <a href=https://github.com/jackyzha0/quartz>Quartz</a>é€™å€‹é…·æ±è¥¿ç¨®å‡ºä¾†ğŸª´ , Â© 2023</p><p><a href=https://www.buymeacoffee.com/htl.lizard><img src=https://cdn.buymeacoffee.com/buttons/v2/default-yellow.png width=200></a></p><ul><li><a href=https://www.physician.tw/>ğŸ é¦–é </a></li><li><a href=https://www.facebook.com/htlin.lizard>Facebook</a></li><li><a href=https://twitter.com/htlin222>Twitter</a></li><li><a href=https://github.com/htlin222>GitHub</a></li><li><a href=https://htlin.site>Blog</a></li><li><a href=https://htlin222.medium.com>Medium</a></li></ul></footer></div></div></body></html>